Value-based pricing in the UK – A discussion of the wider benefits from new medicines

Value-based pricing in the UK – A discussion of the wider benefits from new medicines

Tim Wilsdon
Life Sciences | Pharmaceuticals

Leela Barham and Tim Wilsdon discuss the potential impact that value-based pricing (VBP) may have in the UK and the broader implications for developing international models of Health Technology Assessment (HTA). The article can be found here:

Download PDF